Opus Genetics, Inc. (IRD) AI Stock Analysis

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases and other ophthalmic disorders. Its pipeline includes OPGx-LCA5 in Phase 1/2 clinical trials for LCA5-associated retinal degeneration and OPGx-BEST1 for BEST1-associated retinal disease. Pre-clinical programs include OPGx-RHO, OPGx-RDH12, OPGx-MERTK, OPGx-NMNAT1, and OPGx-CNGB1. The company is also developing Phentolamine Ophthalmic Solution for reversal of mydriasis, presbyopia, and dim light disturbances, alongside APX3330 for diabetic retinopathy.

Opus Genetics grew revenue from $589,000 in FY2021 to $39.9M in FY2022, before falling to $19.0M in FY2023 and $11.0M in FY2024. In FY2025, revenue increased 29.1% to $14.2M, representing a 4-year revenue CAGR of 121.6% from FY2021 to FY2025. Gross margin was 100.0% across all five years. However, net income remained negative in four of the five years, posting -$49.6M in FY2025 with an operating margin of -271.9% and R&D expense of $30.8M. For the latest quarter ended June 30, 2026, quarterly revenue fell 73.8% year-over-year, while trailing twelve months revenue stood at $9.9M with an operating margin of -2182.8% and EPS of -$1.27.

As of June 30, 2026, Opus Genetics reported $88.8M in cash and short-term investments and $34.9M in total debt, yielding net cash of $53.9M. Total assets stood at $93.0M, and the current ratio was 12.19, though shareholders' equity was -$13.0M due to accumulated deficits. In FY2025, operating cash flow and free cash flow were both -$35.3M. Cash allocation included $152,000 in share buybacks during FY2025, while the share count expanded 523.8% over the past 5 years.

At a last close of $3.84 on October 16, 2026, Opus Genetics had a market cap of $319.5M and an enterprise value of $347.6M. The stock traded at a price-to-sales multiple of 32.4x and an enterprise value-to-revenue ratio of 35.3x, substantially above the median of its US-listed Healthcare peers of 4.1x price-to-sales. Its forward P/E was 12.0x, below the peer group median of 17.3x. Over the past 1 year, the stock returned 91.0%, outperforming the S&P 500's return of 16.8%, but its 5-year return of -10.5% lagged the index's 83.0% gain.

Wall Street coverage includes 15 Strong Buy and 3 Buy recommendations, with no Hold, Sell, or Strong Sell ratings. The mean price target is $13.47, implying upside of 250.8% from the last close of $3.84. For the fiscal year ending December 31, 2026, analysts estimate EPS of -$0.94 on revenue of $12.3M. For the next fiscal year, 12 analysts project revenue of $13.6M and EPS of -$0.71. Opus Genetics beat EPS estimates in 1 of the last 4 quarters, and the next earnings date is November 11, 2026.

This page is an AI-written research summary of Opus Genetics, Inc. (IRD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IRD income statement, IRD balance sheet, IRD key metrics, IRD analyst forecast, IRD chart. See the IRD stock overview for the latest quote and news.